INTRODUCTION AND OBJECTIVES:
A curative option in men with biochemical recurrence (BCR) after primary treatment is represented by salvage radical prostatectomy (sRP). To enhance cancer control and benefit-risk ratio, patient selection is definitely the key. According to EAU guidelines, sRP candidates should have low comorbidities, pre-sRP PSA <10 ng/mL, pre-sRP biopsy Gleason Score (GS) 8, no evidence of lymph-node or extra-nodal metastases and previous organ-confined disease. We compared histological and oncological outcomes between patients compliant and non-compliant with these requirements.
METHODS: Seventy-three full-EAU-compliant (lower-risk, Group A) and 236 non-EAU-compliant patients (higher risk, group B) were retrospectively enrolled, drawing from a database of 615 sRP performed between 2000 and 2016 at 18 tertiary referral centres. We assessed pre-, intra and post-procedural clinical and histological data. A follow up <6 months or unavailability of the data were exclusion criteria. Continuous variables were compared using Wilcoxon-MannWhitney test; differences in categorical variables were assessed by Chi-square or Fisher's exact tests.
RESULTS: No significant difference between Group A and B was observed as for median age at sRP (65.57 vs 66.91 years, p[0,11) and follow-up duration (3.43 vs 3.12 years, p[0,16). As obvious, PSA before salvage surgery was significantly higher among Group B patients (5.0 [IQR: 2.5-5.4] vs 3.8 [IQR 2.6 vs 9.0] ng/ml, p[0,01), as well as ASA score and GS distribution at confirmatory biopsy. Organ-confined disease at sRP (pT2) was encountered in 68.5% vs 35.9% (p<0,01), pN1 disease in 7.8% vs 23.5% (p<0,01) and of GS!8 disease in 8.8% vs 56.1% (p<0,01), of men belonging to Group A vs Group B, respectively. In the higher risk group, positive surgical margins were more common (43% vs 27%, p[0,02) . Lowerrisk group showed a nearly doubled BCR-free survival at last followup (64.4% vs 37.9%, p>0,01). Besides, proportions of patients alive at last follow-up were similar: 94,5% vs 93,6% for Group A vs B, respectively.
CONCLUSIONS: For well-selected patients affected by recurrent PCa after non-surgical treatment, sRP entails promising short-term oncological outcomes, along with considerable morbidity. More than the half (64.4%) of men fully-compliant to EAU selection criteria is still disease-free 3 years after sRP. These data suggest that potentially-curative surgical salvage treatment should not be precluded upfront. Large long-term series are needed to confirm sRP benefits and to improve patient selection.
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Wout Devlies*, Leuven, Belgium; Greet De Coster, Nancy Van Damme, Thierry Roumegu ere, Thierry Quakels, Brussels, Belgium; Ben Van Cleynenbreugel, Leuven, Belgium; Peter Dekuyper, Filip Ameye, Ghent, Belgium; Wouter Everaerts, Steven Joniau, Leuven, Belgium INTRODUCTION AND OBJECTIVES: Robotic assisted laparoscopic prostatectomy (RALP) is increasingly used as treatment for high-risk prostate cancer (PCa). However, quality of life (QoL) data in this subgroup is lacking. We evaluated the QoL following RALP in high versus low/intermediate risk PCa patients using the Be-RALP database: a large, prospective, multicentre database.
METHODS: A total of 9235 patients treated by RALP between 2009 and 2016 were included in the database. The EORTC QLQ-C30 questionnaire were completed on baseline, 1-, 3-, 12-and 24-months post-surgery.
Two groups, a high and low-intermediate risk group of 2745 patients each were matched 1:1 using age, year of surgery, nerve sparing and centre size as matching criteria.
Longitudinal mixed models quantified the relation of the QoL changes from baseline with follow-up time, risk group and postoperative radiotherapy (RT)/androgen deprivation therapy (ADT). All models included the two-and three-way interactions of time, risk and postoperative treatment). Backward selection was used to remove nonsignificant interaction terms (AE [ 0.01). Covariates (table 1) corrected for case-mix variation.
RESULTS: Risk was not a significant predictor of QoL (all p>0.07). QoL changed over time and was related to hospital size (all p<0.003). In global, physical and cognitive QoL, surgery year was a significant predictor (all p<0.003). Postoperative treatment was not significant in predicting QoL after surgery (all p>0.04) CONCLUSIONS: Risk group fails to predict quality of life after RALP. Longitudinal figures curves and modelling were risk independent (Figure 1 ). Hospital size was the strongest covariate with better QoL in higher volume centres (all p<0.0001).Longitudinal graphs present a negative effect of postoperative treatment on QoL. This trend is not significant in the mixed effect modelling (p>0.04).
